KR20080084808A - ｒｈＰＤＧＦ-ＢＢ 및 생체적합성 매트릭스를 사용하는상악안면골 보강 - Google Patents
ｒｈＰＤＧＦ-ＢＢ 및 생체적합성 매트릭스를 사용하는상악안면골 보강 Download PDFInfo
- Publication number
- KR20080084808A KR20080084808A KR1020087014535A KR20087014535A KR20080084808A KR 20080084808 A KR20080084808 A KR 20080084808A KR 1020087014535 A KR1020087014535 A KR 1020087014535A KR 20087014535 A KR20087014535 A KR 20087014535A KR 20080084808 A KR20080084808 A KR 20080084808A
- Authority
- KR
- South Korea
- Prior art keywords
- pdgf
- bone
- biocompatible matrix
- biocompatible
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000011159 matrix material Substances 0.000 title claims abstract description 132
- 230000002787 reinforcement Effects 0.000 title claims abstract description 83
- 108010081589 Becaplermin Proteins 0.000 title claims abstract description 49
- 210000003054 facial bone Anatomy 0.000 title claims abstract description 6
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 201
- 239000000203 mixture Substances 0.000 claims abstract description 80
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 74
- 238000000034 method Methods 0.000 claims abstract description 58
- 239000012528 membrane Substances 0.000 claims abstract description 47
- 210000001909 alveolar process Anatomy 0.000 claims abstract description 24
- 210000004373 mandible Anatomy 0.000 claims abstract description 22
- 239000001506 calcium phosphate Substances 0.000 claims abstract description 20
- 235000011010 calcium phosphates Nutrition 0.000 claims abstract description 18
- 210000002050 maxilla Anatomy 0.000 claims abstract description 18
- 229910000389 calcium phosphate Inorganic materials 0.000 claims abstract description 15
- 239000000243 solution Substances 0.000 claims description 95
- 239000011230 binding agent Substances 0.000 claims description 57
- 108010035532 Collagen Proteins 0.000 claims description 47
- 102000008186 Collagen Human genes 0.000 claims description 47
- 229920001436 collagen Polymers 0.000 claims description 47
- 230000007812 deficiency Effects 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 12
- 239000000872 buffer Substances 0.000 claims description 11
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims description 5
- 108010000685 platelet-derived growth factor AB Proteins 0.000 claims description 5
- 239000000833 heterodimer Substances 0.000 claims description 4
- 108010017992 platelet-derived growth factor C Proteins 0.000 claims description 4
- 239000008351 acetate buffer Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 abstract description 178
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 abstract description 178
- 239000000463 material Substances 0.000 abstract description 71
- 239000007943 implant Substances 0.000 abstract description 46
- 230000001737 promoting effect Effects 0.000 abstract description 12
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 2
- 239000002245 particle Substances 0.000 description 43
- 238000001356 surgical procedure Methods 0.000 description 30
- 238000002513 implantation Methods 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 241000283690 Bos taurus Species 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 12
- 210000004872 soft tissue Anatomy 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 11
- 239000010936 titanium Substances 0.000 description 11
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 10
- 239000013543 active substance Substances 0.000 description 10
- 229910052719 titanium Inorganic materials 0.000 description 10
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 230000009969 flowable effect Effects 0.000 description 9
- 230000035876 healing Effects 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000011148 porous material Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000003416 augmentation Effects 0.000 description 7
- -1 polytetrafluoroethylene Polymers 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000008468 bone growth Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 230000003239 periodontal effect Effects 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000010072 bone remodeling Effects 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108010009565 Bio-Gide Proteins 0.000 description 4
- 229920001661 Chitosan Polymers 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 230000001054 cortical effect Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000004023 fresh frozen plasma Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000004623 platelet-rich plasma Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000000503 Collagen Type II Human genes 0.000 description 3
- 108010041390 Collagen Type II Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000002695 general anesthesia Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002690 local anesthesia Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000007838 tissue remodeling Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010027258 GEM 21S Proteins 0.000 description 2
- 229920000544 Gore-Tex Polymers 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000003592 biomimetic effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 150000004663 bisphosphonates Chemical class 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- ZBZJARSYCHAEND-UHFFFAOYSA-L calcium;dihydrogen phosphate;hydrate Chemical compound O.[Ca+2].OP(O)([O-])=O.OP(O)([O-])=O ZBZJARSYCHAEND-UHFFFAOYSA-L 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000001925 catabolic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000023753 dehiscence Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium phosphate dihydrate Substances O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000020938 metabolic status Nutrition 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 230000004819 osteoinduction Effects 0.000 description 2
- 230000002138 osteoinductive effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003634 thrombocyte concentrate Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QHQZEEGNGSZBOL-UHFFFAOYSA-N 2-(aminomethyl)-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(CO)(CO)CO QHQZEEGNGSZBOL-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- NYEZZYQZRQDLEH-UHFFFAOYSA-N 2-ethyl-4,5-dihydro-1,3-oxazole Chemical compound CCC1=NCCO1 NYEZZYQZRQDLEH-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- RFRMMZAKBNXNHE-UHFFFAOYSA-N 6-[4,6-dihydroxy-5-(2-hydroxyethoxy)-2-(hydroxymethyl)oxan-3-yl]oxy-2-(hydroxymethyl)-5-(2-hydroxypropoxy)oxane-3,4-diol Chemical compound CC(O)COC1C(O)C(O)C(CO)OC1OC1C(O)C(OCCO)C(O)OC1CO RFRMMZAKBNXNHE-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002518 Polyallylamine hydrochloride Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical group 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 210000004763 bicuspid Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000034127 bone morphogenesis Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 239000000316 bone substitute Substances 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- OLSDWRNWUGHKSY-UHFFFAOYSA-J dicalcium;phosphonato phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O OLSDWRNWUGHKSY-UHFFFAOYSA-J 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- YIOJGTBNHQAVBO-UHFFFAOYSA-N dimethyl-bis(prop-2-enyl)azanium Chemical compound C=CC[N+](C)(C)CC=C YIOJGTBNHQAVBO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229910000150 monocalcium phosphate Inorganic materials 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920006209 poly(L-lactide-co-D,L-lactide) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920005583 poly(anhydride-co-imide) Polymers 0.000 description 1
- 229920000117 poly(dioxanone) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920001042 poly(δ-valerolactone) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001299 polypropylene fumarate Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- LFULEKSKNZEWOE-UHFFFAOYSA-N propanil Chemical compound CCC(=O)NC1=CC=C(Cl)C(Cl)=C1 LFULEKSKNZEWOE-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003232 water-soluble binding agent Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/42—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
- A61L27/425—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of phosphorus containing material, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C8/00—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
- A61C8/0003—Not used, see subgroups
- A61C8/0004—Consolidating natural teeth
- A61C8/0006—Periodontal tissue or bone regeneration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2/2803—Bones for mandibular reconstruction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2/2846—Support means for bone substitute or for bone graft implants, e.g. membranes or plates for covering bone defects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2817—Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00179—Ceramics or ceramic-like structures
- A61F2310/00293—Ceramics or ceramic-like structures containing a phosphorus-containing compound, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Dentistry (AREA)
- Developmental Biology & Embryology (AREA)
- Plastic & Reconstructive Surgery (AREA)
- Materials For Medical Uses (AREA)
- Dental Preparations (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73807605P | 2005-11-17 | 2005-11-17 | |
| US60/738,076 | 2005-11-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20080084808A true KR20080084808A (ko) | 2008-09-19 |
Family
ID=38067796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020087014535A Ceased KR20080084808A (ko) | 2005-11-17 | 2006-11-17 | ｒｈＰＤＧＦ-ＢＢ 및 생체적합성 매트릭스를 사용하는상악안면골 보강 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8114841B2 (enExample) |
| EP (2) | EP1951327A2 (enExample) |
| JP (1) | JP5368102B2 (enExample) |
| KR (1) | KR20080084808A (enExample) |
| CN (1) | CN101370531A (enExample) |
| BR (1) | BRPI0618794A2 (enExample) |
| CA (1) | CA2630077C (enExample) |
| NO (1) | NO20082393L (enExample) |
| NZ (1) | NZ571113A (enExample) |
| WO (1) | WO2007061889A2 (enExample) |
| ZA (1) | ZA200804548B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040081704A1 (en) | 1998-02-13 | 2004-04-29 | Centerpulse Biologics Inc. | Implantable putty material |
| US20020114795A1 (en) | 2000-12-22 | 2002-08-22 | Thorne Kevin J. | Composition and process for bone growth and repair |
| US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
| KR20080084808A (ko) | 2005-11-17 | 2008-09-19 | 바이오미메틱 세라퓨틱스, 인크. | ｒｈＰＤＧＦ-ＢＢ 및 생체적합성 매트릭스를 사용하는상악안면골 보강 |
| EP2311505B1 (en) * | 2006-02-09 | 2013-11-06 | BioMimetic Therapeutics, LLC | Compositions and methods for treating bone |
| US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
| EP3381463A1 (en) | 2006-06-30 | 2018-10-03 | BioMimetic Therapeutics, LLC | Pdgf-biomatrix compositions and methods for treating rotator cuff injuries |
| CA2668189C (en) | 2006-11-03 | 2016-01-26 | Biomimetic Therapeutics, Inc. | Compositions and methods for arthrodetic procedures comprising a solution of platelet derived growth factor (pdgf) incorporated in a biocompatible matrix |
| US7718616B2 (en) | 2006-12-21 | 2010-05-18 | Zimmer Orthobiologics, Inc. | Bone growth particles and osteoinductive composition thereof |
| EP2144613B1 (en) | 2006-12-29 | 2018-03-21 | OstéoQC Inc. | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| US20100151025A1 (en) * | 2007-02-20 | 2010-06-17 | Biomimetic Therapeutics, Inc. | Prevention and treatment for osteonecrosis and osteoradionecrosis of the jaw |
| US20090042158A1 (en) * | 2007-08-09 | 2009-02-12 | Gregory Gene Steiner | Method for regenerating bone in the maxillary sinus |
| CN102014977B (zh) | 2008-02-07 | 2015-09-02 | 生物模拟治疗有限责任公司 | 用于牵引成骨术的组合物和方法 |
| US9616153B2 (en) * | 2008-04-17 | 2017-04-11 | Warsaw Orthopedic, Inc. | Rigid bone graft substitute |
| CN102231992B (zh) | 2008-09-09 | 2015-05-20 | 生物模拟治疗公司 | 用于治疗肌腱和韧带损伤的血小板衍生生长因子的组合物和方法 |
| EP2376106A4 (en) * | 2008-12-19 | 2013-01-09 | Biomimetic Therapeutics Inc | BONE TRANSPLANTS WITH REDUCED PROTEASE EFFECT AND SELECTION AND APPLICATION PROCEDURES |
| US20100247651A1 (en) * | 2009-03-05 | 2010-09-30 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods for the treatment of osteochondral defects |
| WO2011038354A1 (en) * | 2009-09-25 | 2011-03-31 | Tuffs University | Dental graft for treating periodontal conditions and thin biotypes |
| US8994666B2 (en) * | 2009-12-23 | 2015-03-31 | Colin J. Karpfinger | Tactile touch-sensing interface system |
| NZ601559A (en) * | 2010-02-22 | 2014-10-31 | Biomimetic Therapeutics Llc | Platelet-derived growth factor compositions and methods for the treatment of tendinopathies |
| CA2817584C (en) | 2010-11-15 | 2018-01-02 | Zimmer Orthobiologics, Inc. | Bone void fillers |
| CN108498873A (zh) * | 2010-12-13 | 2018-09-07 | 生物模拟治疗有限责任公司 | 用于脊柱融合手术的组合物和方法 |
| US8551525B2 (en) | 2010-12-23 | 2013-10-08 | Biostructures, Llc | Bone graft materials and methods |
| WO2012118843A1 (en) * | 2011-02-28 | 2012-09-07 | Tissue Regeneration Systems, Inc. | Modular tissue scaffolds |
| JP6188578B2 (ja) * | 2012-02-01 | 2017-08-30 | 株式会社オーガンテクノロジーズ | 歯科用インプラントおよびその製造方法 |
| CN105085652B (zh) * | 2014-05-16 | 2021-06-22 | 中国人民解放军军事医学科学院生物工程研究所 | 血小板衍生生长因子b突变体、其制备方法及用途 |
| JP6871855B2 (ja) * | 2014-10-14 | 2021-05-19 | サムエル リンチ， | 創傷を処置するための組成物 |
| WO2016126220A1 (en) * | 2015-02-04 | 2016-08-11 | Polat Serkan | Membrane system for forming bone without graft |
| CN105126172B (zh) * | 2015-09-28 | 2017-12-12 | 武汉大学 | 一种增高牙槽嵴的牙支架的制备及安装方法 |
| US20230120120A1 (en) * | 2016-11-18 | 2023-04-20 | Cutting Edge Technology, LLC | Pharmaceutical formulation |
| CN110236710A (zh) * | 2018-03-09 | 2019-09-17 | 中日友好医院 | 一种促进植骨材料在牙种植上颌窦外提升术后成骨的方法 |
| US12419752B2 (en) * | 2019-11-27 | 2025-09-23 | Igor Roshkovan | Surgical technique for alveolar ridge augmentation with maxillary sinus elevation (lateral approach) using a pre-portioned and ready pre-packaged bone graft composition in gelatin bag and method of producing it |
Family Cites Families (223)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3943072A (en) | 1971-12-15 | 1976-03-09 | United Kingdom Atomic Energy Authority | Separation of molecules |
| USRE33161E (en) | 1982-04-29 | 1990-02-06 | American Dental Association Health Foundation | Combinations of sparingly soluble calcium phosphates in slurries and pastes as mineralizers and cements |
| US4654314A (en) | 1983-07-09 | 1987-03-31 | Sumitomo Cement Co., Ltd. | Porous ceramic material and processes for preparing same |
| US5187263A (en) | 1984-10-12 | 1993-02-16 | Zymogenetics, Inc. | Expression of biologically active PDGE analogs in eucaryotic cells |
| US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| US4889919A (en) | 1986-08-13 | 1989-12-26 | Zymogenetics, Inc. | Biologically active PDGF derived A-chain homodimers |
| US5165938A (en) | 1984-11-29 | 1992-11-24 | Regents Of The University Of Minnesota | Wound healing agents derived from platelets |
| US5629191A (en) | 1985-01-03 | 1997-05-13 | Integra Lifesciences Corporation | Method of making a porous matrix particle |
| US5045633A (en) | 1985-02-25 | 1991-09-03 | Zymogenetics, Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| US5516896A (en) | 1985-02-25 | 1996-05-14 | Zymogenetics, Inc. | Biologically active B-chain homodimers |
| CA1260391A (en) * | 1985-03-28 | 1989-09-26 | Karl A. Piez | Xenogeneic collagen/mineral preparations in bone repair |
| DE3530825A1 (de) * | 1985-08-29 | 1987-03-05 | Boehringer Mannheim Gmbh | Neue benzodipyrrole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| ZA874681B (en) | 1986-07-01 | 1988-04-27 | Genetics Inst | Novel osteoinductive factors |
| US5013649A (en) | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
| US5106748A (en) | 1986-07-01 | 1992-04-21 | Genetics Institute, Inc. | Dna sequences encoding 5 proteins |
| US5108922A (en) | 1986-07-01 | 1992-04-28 | Genetics Institute, Inc. | DNA sequences encoding BMP-1 products |
| US5187076A (en) | 1986-07-01 | 1993-02-16 | Genetics Institute, Inc. | DNA sequences encoding BMP-6 proteins |
| CA1322714C (en) | 1986-11-14 | 1993-10-05 | Harry N. Antoniades | Wound healing and bone regeneration |
| IE60517B1 (en) | 1986-11-14 | 1994-07-27 | Inst Molecular Biology Inc | Wound healing and bone regeneration |
| US5019559A (en) | 1986-11-14 | 1991-05-28 | President And Fellows Of Harvard College | Wound healing using PDGF and IGF-II |
| US5124316A (en) | 1986-11-14 | 1992-06-23 | President And Fellows Of Harvard College | Method for periodontal regeneration |
| US5219759A (en) | 1987-04-22 | 1993-06-15 | Chiron Corporation | Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors |
| US5457093A (en) | 1987-09-18 | 1995-10-10 | Ethicon, Inc. | Gel formulations containing growth factors |
| US4874746A (en) | 1987-12-22 | 1989-10-17 | Institute Of Molecular Biology, Inc. | Wound headling composition of TGF-alpha and PDGF |
| US5759815A (en) | 1988-02-11 | 1998-06-02 | Creative Biomolecules, Inc. | Production of platelet derived growth factor (PDGF) an muteins thereof |
| US6586388B2 (en) | 1988-04-08 | 2003-07-01 | Stryker Corporation | Method of using recombinant osteogenic protein to repair bone or cartilage defects |
| US4975526A (en) | 1989-02-23 | 1990-12-04 | Creative Biomolecules, Inc. | Bone collagen matrix for zenogenic implants |
| US5053212A (en) | 1988-04-20 | 1991-10-01 | Norian Corporation | Intimate mixture of calcium and phosphate sources as precursor to hydroxyapatite |
| US5129905A (en) | 1988-04-20 | 1992-07-14 | Norian Corporation | Methods for in situ prepared calcium phosphate minerals |
| US5962028A (en) | 1988-04-20 | 1999-10-05 | Norian Corporation | Carbonated hydroxyapatite compositions and uses |
| US4904259A (en) | 1988-04-29 | 1990-02-27 | Samuel Itay | Compositions and methods for repair of cartilage and bone |
| US5219576A (en) | 1988-06-30 | 1993-06-15 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| US5034375A (en) | 1988-08-10 | 1991-07-23 | Institute Of Molecular Biology, Inc. | Process of wound healing using PDGF and EGF |
| US6028105A (en) * | 1989-04-06 | 2000-02-22 | Nigra; Thomas P. | Topical drug delivery composition and method |
| US5035887A (en) | 1989-09-07 | 1991-07-30 | Institute Of Moelcular Biology, Inc. | Wound healing composition of IL-1 and PDGF or IGF-1 |
| US5599558A (en) | 1989-09-15 | 1997-02-04 | Curative Technologies, Inc. | Selecting amounts of platelet releasate for efficacious treatment of tissue |
| US5112354A (en) | 1989-11-16 | 1992-05-12 | Northwestern University | Bone allograft material and method |
| US5011910A (en) | 1989-12-28 | 1991-04-30 | Washington University | Reagent and method for determining activity of retroviral protease |
| CA2075196A1 (en) | 1990-02-01 | 1991-08-02 | Gary R. Grotendorst | Leukocyte-derived growth factor |
| TW199858B (enExample) | 1990-03-30 | 1993-02-11 | Fujirebio Kk | |
| CA2060208C (en) | 1990-04-10 | 2001-02-20 | Harry N. Antoniades | Wound healing |
| US5108322A (en) * | 1990-07-24 | 1992-04-28 | Zebco Corporation | Relay control of auxiliary functions in a trolling motor |
| US5853746A (en) * | 1991-01-31 | 1998-12-29 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone using functional barrier |
| US5149691A (en) | 1991-03-12 | 1992-09-22 | Creative Biomolecules, Inc. | Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone |
| DE4120325A1 (de) | 1991-06-20 | 1992-12-24 | Merck Patent Gmbh | Implantatwerkstoff |
| US5837258A (en) | 1991-08-30 | 1998-11-17 | University Of South Florida | Induction of tissue, bone or cartilage formation using connective tissue growth factor |
| US5270300A (en) | 1991-09-06 | 1993-12-14 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone |
| EP0691849B1 (en) | 1993-03-29 | 1999-06-02 | ZymoGenetics, Inc. | Oesteoblast growth stimulating compostion containing pdgf and vitamin d |
| AU7205894A (en) | 1993-06-08 | 1995-01-03 | Neogenix, Inc. | Purified natural and synthetic compounds for the treatment of osteoarthritis |
| US5531794A (en) | 1993-09-13 | 1996-07-02 | Asahi Kogaku Kogyo Kabushiki Kaisha | Ceramic device providing an environment for the promotion and formation of new bone |
| US5518680A (en) | 1993-10-18 | 1996-05-21 | Massachusetts Institute Of Technology | Tissue regeneration matrices by solid free form fabrication techniques |
| JP3362267B2 (ja) | 1993-12-29 | 2003-01-07 | 日本特殊陶業株式会社 | 生体インプラント材料及びその製造方法 |
| US5460962A (en) | 1994-01-04 | 1995-10-24 | Organogenesis Inc. | Peracetic acid sterilization of collagen or collagenous tissue |
| US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
| US7963997B2 (en) | 2002-07-19 | 2011-06-21 | Kensey Nash Corporation | Device for regeneration of articular cartilage and other tissue |
| US6180606B1 (en) | 1994-09-28 | 2001-01-30 | Gensci Orthobiologics, Inc. | Compositions with enhanced osteogenic potential, methods for making the same and uses thereof |
| US5651766A (en) | 1995-06-07 | 1997-07-29 | Transfusion Technologies Corporation | Blood collection and separation system |
| US5614206A (en) | 1995-03-07 | 1997-03-25 | Wright Medical Technology, Inc. | Controlled dissolution pellet containing calcium sulfate |
| US5635372A (en) | 1995-05-18 | 1997-06-03 | Genetics Institute, Inc. | BMP-15 compositions |
| US5676976A (en) | 1995-05-19 | 1997-10-14 | Etex Corporation | Synthesis of reactive amorphous calcium phosphates |
| US6027742A (en) | 1995-05-19 | 2000-02-22 | Etex Corporation | Bioresorbable ceramic composites |
| US6541037B1 (en) | 1995-05-19 | 2003-04-01 | Etex Corporation | Delivery vehicle |
| US6287341B1 (en) | 1995-05-19 | 2001-09-11 | Etex Corporation | Orthopedic and dental ceramic implants |
| EP1486565B1 (en) | 1995-10-11 | 2007-11-21 | Novartis Vaccines and Diagnostics, Inc. | Combination of PDGF, KGF, IGF, and IGFBP for wound healing |
| US5783217A (en) | 1995-11-07 | 1998-07-21 | Etex Corporation | Low temperature calcium phosphate apatite and a method of its manufacture |
| US5747273A (en) | 1996-05-07 | 1998-05-05 | Diagnostic Systems Laboratories, Inc. | Immunoassay of total insulin-like growth factor binding protein-1 |
| US6077989A (en) | 1996-05-28 | 2000-06-20 | Kandel; Rita | Resorbable implant biomaterial made of condensed calcium phosphate particles |
| FR2749756B1 (fr) | 1996-06-14 | 1998-09-11 | Bioland | Procede de preparation d'un materiau composite implantable, materiau obtenu, implant comprenant ce materiau et kit de mise en oeuvre |
| US5965403A (en) | 1996-09-18 | 1999-10-12 | Genetics Institute, Inc. | Nucleic acids encoding bone morphogenic protein-16 (BMP-16) |
| JP4260891B2 (ja) | 1996-10-16 | 2009-04-30 | エテックス コーポレイション | 生体セラミック組成物 |
| US6037519A (en) | 1997-10-20 | 2000-03-14 | Sdgi Holdings, Inc. | Ceramic fusion implants and compositions |
| DE19646782C2 (de) | 1996-11-13 | 2000-05-25 | Merck Patent Gmbh | Bioresorbierbare Polymerisationsprodukte aus strahlungshärtbaren Bindemittelsystemen |
| EP0948538B1 (en) | 1996-12-13 | 2008-06-11 | Novartis Vaccines and Diagnostics, Inc. | Analysis and separation of platelet-derived growth factor proteins |
| US5866165A (en) | 1997-01-15 | 1999-02-02 | Orquest, Inc. | Collagen-polysaccharide matrix for bone and cartilage repair |
| FR2758988B1 (fr) | 1997-02-05 | 2000-01-21 | S H Ind | Procede d'elaboration de substituts osseux synthetiques d'architecture poreuse parfaitement maitrisee |
| EP2332564A1 (en) | 1997-02-07 | 2011-06-15 | Stryker Corporation | Matrix-free osteogenic devices, implants and methods thereof |
| DE69823955T2 (de) | 1997-03-04 | 2005-06-16 | Technology Finance Corp. (Pty.) Ltd., Sandton | Als knochenimplantat geeignetes erzeugnis |
| US20020098222A1 (en) | 1997-03-13 | 2002-07-25 | John F. Wironen | Bone paste |
| US7041641B2 (en) | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
| US20010016646A1 (en) | 1998-03-20 | 2001-08-23 | David C. Rueger | Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects |
| JP3334558B2 (ja) | 1997-04-23 | 2002-10-15 | 富士レビオ株式会社 | 酵素免疫測定方法及び試験片 |
| US20030032586A1 (en) | 1997-05-15 | 2003-02-13 | David C. Rueger | Compositions for morphogen-induced osteogenesis |
| GB2325934A (en) | 1997-06-03 | 1998-12-09 | Polybiomed Ltd | Treating metal surfaces to enhance bio-compatibility and/or physical characteristics |
| US6063624A (en) | 1997-06-09 | 2000-05-16 | Baxter International Inc. | Platelet suspensions and methods for resuspending platelets |
| DE69714035T2 (de) | 1997-08-14 | 2003-03-06 | Sulzer Innotec Ag, Winterthur | Zusammensetzung und Vorrichtung zur Reparatur von Knorpelgewebe in vivo bestehend aus Nanokapseln mit osteoinduktiven und/oder chondroinduktiven Faktoren |
| US6136029A (en) | 1997-10-01 | 2000-10-24 | Phillips-Origen Ceramic Technology, Llc | Bone substitute materials |
| US6090998A (en) | 1997-10-27 | 2000-07-18 | University Of Florida | Segmentally demineralized bone implant |
| US20020018796A1 (en) | 1998-01-28 | 2002-02-14 | John F. Wironen | Thermally sterilized bone paste |
| PT1100488E (pt) | 1998-07-28 | 2003-09-30 | Synthes Ag | Utilizacao de compostos de creatina para tratamento das celulas e tecidos do osso ou cartilagem |
| US20030114936A1 (en) | 1998-10-12 | 2003-06-19 | Therics, Inc. | Complex three-dimensional composite scaffold resistant to delimination |
| US6224635B1 (en) | 1998-11-06 | 2001-05-01 | Hospital For Joint Diseases | Implantation of surgical implants with calcium sulfate |
| US6663870B2 (en) | 1998-12-07 | 2003-12-16 | Zymogenetics, Inc. | Methods for promoting growth of bone using zvegf3 |
| US6231528B1 (en) | 1999-01-15 | 2001-05-15 | Jonathan J. Kaufman | Ultrasonic and growth factor bone-therapy: apparatus and method |
| EP1025871A1 (en) | 1999-01-28 | 2000-08-09 | F. Hoffmann-La Roche Ag | Use of a melanoma inhibiting activity factor (MIA) for cartilage and bone repair |
| DE60006356T2 (de) | 1999-02-04 | 2004-09-09 | SDGI Holding, Inc., Wilmington | Hochmineralisierte osteogene schwammzusammensetzungen und ihre verwendung |
| US6294187B1 (en) | 1999-02-23 | 2001-09-25 | Osteotech, Inc. | Load-bearing osteoimplant, method for its manufacture and method of repairing bone using same |
| KR20010043639A (ko) | 1999-03-15 | 2001-05-25 | 키이스 디 | 혈소판 수거 시스템 |
| US6296602B1 (en) | 1999-03-17 | 2001-10-02 | Transfusion Technologies Corporation | Method for collecting platelets and other blood components from whole blood |
| ES2199815T3 (es) | 1999-03-19 | 2004-03-01 | The Regents Of The University Of Michigan | Mineralizacion y desarrollo celular supeerficial sobre biomateriales. |
| US6398972B1 (en) | 1999-04-12 | 2002-06-04 | Harvest Technologies Corporation | Method for producing platelet rich plasma and/or platelet concentrate |
| SE515227C2 (sv) | 1999-04-28 | 2001-07-02 | Bruce Medical Ab | Kropp för åstadkommande av in- och tillväxt av benvävnad och/ eller bindväv och sätt för framställning av kroppen |
| US6468543B1 (en) | 1999-05-03 | 2002-10-22 | Zymogenetics, Inc. | Methods for promoting growth of bone using ZVEGF4 |
| US6710025B1 (en) | 1999-05-26 | 2004-03-23 | The Brigham And Women's Hospital, Inc. | Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin |
| AU5444800A (en) | 1999-05-27 | 2000-12-18 | Research Foundation Of State University Of New York, The | LTiGTin vitroLT/iGT cell culture device including cartilage and methods of usingthe same |
| DE19926083A1 (de) | 1999-06-08 | 2000-12-14 | Universitaetsklinikum Freiburg | Biologisches Gelenkkonstrukt |
| US6429013B1 (en) | 1999-08-19 | 2002-08-06 | Artecel Science, Inc. | Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair |
| DE19940717A1 (de) | 1999-08-26 | 2001-03-01 | Gerontocare Gmbh | Resorblerbares Knochenersatz- und Knochenaufbaumaterial |
| US6280191B1 (en) | 1999-09-03 | 2001-08-28 | Christopher B. Gordon | Distractor suitable for permanent implantation into bone |
| JP4809963B2 (ja) * | 1999-11-11 | 2011-11-09 | オリンパス株式会社 | 骨補填材 |
| US6451059B1 (en) | 1999-11-12 | 2002-09-17 | Ethicon, Inc. | Viscous suspension spinning process for producing resorbable ceramic fibers and scaffolds |
| EP1255576B1 (en) | 1999-12-09 | 2003-08-20 | Biosyntech Canada Inc. | Mineral-polymer hybrid composition |
| US6479418B2 (en) | 1999-12-16 | 2002-11-12 | Isotis N.V. | Porous ceramic body |
| US20030103960A1 (en) | 1999-12-22 | 2003-06-05 | Pierre Philippart | Sealant and bone generating product |
| CA2396016A1 (en) * | 1999-12-29 | 2001-07-05 | Andy Bernhardt | System for reconstituting pastes and methods of using same |
| AU4234901A (en) | 2000-01-28 | 2001-08-07 | Dot Dunnschicht Und Oberflache | Inorganic resorbable bone substitute material and production method |
| WO2001057083A1 (en) | 2000-02-04 | 2001-08-09 | Zymogenetics, Inc. | Methods for promoting growth of bone, ligament, and cartilage using zvegf4 |
| CA2399224A1 (en) | 2000-02-18 | 2001-08-23 | Regeneration Technologies, Inc. | Implantable tissues infused with growth factors and other additives |
| IT1316769B1 (it) | 2000-02-18 | 2003-05-12 | Getters Spa | Pannello evacuato per isolamento termico con ridotta conduzione dicalore ai bordi |
| US7022506B2 (en) | 2000-02-23 | 2006-04-04 | The Trustees Of The University Of Pennsylvania | Method and device for treating osteoarthritis, cartilage disease, defects and injuries in the human knee |
| US20030055511A1 (en) | 2000-03-03 | 2003-03-20 | Schryver Jeffrey E. | Shaped particle comprised of bone material and method of making the particle |
| EP1259196A2 (en) * | 2000-03-03 | 2002-11-27 | Smith & Nephew, Inc. | Shaped particle and composition for bone deficiency and method of making the particle |
| US20030125252A1 (en) | 2000-03-14 | 2003-07-03 | Underhill T. Michael | Compositions and methods for affecting osteogenesis |
| US20020006437A1 (en) | 2000-05-01 | 2002-01-17 | Grooms Jamie M. | Non-migration tissue capsule |
| US20020022885A1 (en) | 2000-05-19 | 2002-02-21 | Takahiro Ochi | Biomaterial |
| EP1287506A2 (en) | 2000-05-19 | 2003-03-05 | Europrint Holdings Limited | Method and system for implementing a game |
| US20020082220A1 (en) | 2000-06-29 | 2002-06-27 | Hoemann Caroline D. | Composition and method for the repair and regeneration of cartilage and other tissues |
| DK177997B1 (da) | 2000-07-19 | 2015-02-23 | Ed Geistlich Söhne Ag Für Chemische Ind | Knoglemateriale og collagenkombination til opheling af beskadigede led |
| US6739112B1 (en) | 2000-08-21 | 2004-05-25 | Nu Vasive, Inc. | Bone allograft packaging system |
| GB0020610D0 (en) | 2000-08-21 | 2000-10-11 | Dytech Corp Ltd | Uses of porous carriers |
| US6773723B1 (en) | 2000-08-30 | 2004-08-10 | Depuy Acromed, Inc. | Collagen/polysaccharide bilayer matrix |
| AU2002211850B2 (en) | 2000-10-31 | 2006-07-13 | Depuy Spine, Inc. | Mineralized collagen-polysaccharide matrix for bone and cartilage repair |
| CA2365376C (en) | 2000-12-21 | 2006-03-28 | Ethicon, Inc. | Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
| US20020127265A1 (en) | 2000-12-21 | 2002-09-12 | Bowman Steven M. | Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
| US7192604B2 (en) | 2000-12-22 | 2007-03-20 | Ethicon, Inc. | Implantable biodegradable devices for musculoskeletal repair or regeneration |
| CA2436162A1 (en) | 2001-01-25 | 2002-08-01 | John F. Wironen | Injectable porous bone graft materials |
| US7005135B2 (en) | 2001-01-30 | 2006-02-28 | Ethicon Inc. | Glass scaffolds with controlled resorption rates and methods for making same |
| KR100877484B1 (ko) * | 2001-02-22 | 2009-01-12 | 파나소닉 주식회사 | 광 디스크 장치 |
| JP2004521128A (ja) | 2001-02-23 | 2004-07-15 | ワイス | Ｂｍｐによるヒト骨髄由来ｃｄ１０５＋細胞の軟骨形成能 |
| US6575986B2 (en) | 2001-02-26 | 2003-06-10 | Ethicon, Inc. | Scaffold fixation device for use in articular cartilage repair |
| US6743232B2 (en) | 2001-02-26 | 2004-06-01 | David W. Overaker | Tissue scaffold anchor for cartilage repair |
| US20030049328A1 (en) | 2001-03-02 | 2003-03-13 | Dalal Paresh S. | Porous beta-tricalcium phosphate granules and methods for producing same |
| US6949251B2 (en) | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
| JP2003010310A (ja) * | 2001-06-27 | 2003-01-14 | Olympus Optical Co Ltd | 頭蓋骨用骨補填材料および補填方法 |
| US20030109537A1 (en) | 2001-07-09 | 2003-06-12 | Turner Russell T. | Methods and materials for treating bone conditions |
| DE60219646T2 (de) | 2001-09-24 | 2007-12-27 | Millenium Biologix Technologies Inc., Kingston | Poröse keramische komposit-knochenimplantate |
| WO2003033677A2 (en) | 2001-10-19 | 2003-04-24 | Zymogenetics, Inc. | Dimerized growth factor and materials and methods for producing it |
| US6649072B2 (en) | 2001-11-16 | 2003-11-18 | Robert Brandt | Method for producing autologous platelet-rich plasma |
| AU2002365969A1 (en) | 2001-11-20 | 2003-06-10 | Scott Bruder | Flowable osteogenic and chondrogenic compositions |
| US7045105B2 (en) | 2001-12-21 | 2006-05-16 | Lagow Richard J | Calcium phosphate bone replacement materials and methods of use thereof |
| US7241593B2 (en) | 2002-02-11 | 2007-07-10 | Zymogenetics, Inc. | Materials and methods for preparing dimeric growth factors |
| WO2003070186A2 (en) | 2002-02-20 | 2003-08-28 | The Cleveland Clinic Foundation | Composition and method for inducing bone growth and healing |
| JP3739715B2 (ja) | 2002-03-19 | 2006-01-25 | オリンパス株式会社 | 人工骨および組織工学用担体 |
| KR100460685B1 (ko) | 2002-04-10 | 2004-12-09 | 재단법인서울대학교산학협력재단 | 인산칼슘계 화합물을 이용한 인공 골 충진재 및 그 제조방법 |
| WO2003089022A1 (en) | 2002-04-18 | 2003-10-30 | University Of Florida | Biomimetic organic/inorganic composites, processes for their production, and methods of use |
| JP2005530819A (ja) * | 2002-05-02 | 2005-10-13 | オステオスクリーン，インコーポレイテッド | 一酸化窒素を放出するビスホスホネート結合体（ｎｏ−ビスホスホネート）を使用して骨増殖を刺激するための、方法および組成物 |
| JP2005524710A (ja) | 2002-05-06 | 2005-08-18 | ジェネンテック・インコーポレーテッド | 骨欠陥の治療へのｖｅｇｆの用途 |
| US7368125B2 (en) | 2002-06-05 | 2008-05-06 | Ethicon, Inc. | Amphiphilic polymers for medical applications |
| US7041309B2 (en) | 2002-06-13 | 2006-05-09 | Neuropro Technologies, Inc. | Spinal fusion using an HMG-CoA reductase inhibitor |
| CA2432583A1 (en) | 2002-06-20 | 2003-12-20 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Method of preparing alpha- and beta-tricalcium phosphate powders |
| US20040002770A1 (en) | 2002-06-28 | 2004-01-01 | King Richard S. | Polymer-bioceramic composite for orthopaedic applications and method of manufacture thereof |
| ATE295744T1 (de) | 2002-07-11 | 2005-06-15 | Biomet Deutschland Gmbh | Verfahren zur herstellung poröser calciumphosphatstückchen und -granulaten aus der gelatineverarbeitung |
| DE10240083A1 (de) * | 2002-08-30 | 2004-03-11 | Austriamicrosystems Ag | Verfahren zur Kalibrierung einer Fotodiode, Halbleiterchip und Betriebsverfahren |
| US7744651B2 (en) | 2002-09-18 | 2010-06-29 | Warsaw Orthopedic, Inc | Compositions and methods for treating intervertebral discs with collagen-based materials |
| ES2393321T3 (es) | 2002-10-10 | 2012-12-20 | Ono Pharmaceutical Co., Ltd. | Promotores de la producción de factores de reparación endógenos |
| US20040078090A1 (en) | 2002-10-18 | 2004-04-22 | Francois Binette | Biocompatible scaffolds with tissue fragments |
| US7824701B2 (en) | 2002-10-18 | 2010-11-02 | Ethicon, Inc. | Biocompatible scaffold for ligament or tendon repair |
| AU2003203316B2 (en) * | 2003-02-13 | 2007-01-11 | Synthes Gmbh | Injectable bone-replacement mixture |
| WO2004073563A2 (en) | 2003-02-14 | 2004-09-02 | Depuy Spine, Inc. | In-situ formed intervertebral fusion device |
| JP4198154B2 (ja) * | 2003-02-26 | 2008-12-17 | サイエンスパーク株式会社 | 印刷制御用プログラムを格納した電子計算機、そのプログラム及びプログラム記録媒体 |
| US20040243133A1 (en) | 2003-03-05 | 2004-12-02 | Therics, Inc. | Method and system for manufacturing biomedical articles, such as using biomedically compatible infiltrant metal alloys in porous matrices |
| US20040193270A1 (en) | 2003-03-31 | 2004-09-30 | Depuyacromed, Inc. | Implantable bone graft |
| US7901457B2 (en) | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
| NZ544050A (en) | 2003-06-11 | 2009-03-31 | Osteotech Inc | Osteoimplants and methods for their manufacture |
| US6974862B2 (en) | 2003-06-20 | 2005-12-13 | Kensey Nash Corporation | High density fibrous polymers suitable for implant |
| ES2306826T3 (es) | 2003-06-24 | 2008-11-16 | Dr. H. C. Robert Mathys Foundation | Dispositivo ortopedico para la reparacion de cartilagos. |
| DE10328892A1 (de) | 2003-06-26 | 2005-05-12 | Curasan Ag | Knochenaufbaumittel und Herstellungsverfahren |
| AU2004252568B2 (en) | 2003-06-27 | 2011-06-30 | Ethicon, Incorporated | Regeneration and repair of neural tissue using postpartum-derived cells |
| FI20031120A0 (fi) | 2003-07-31 | 2003-07-31 | Bci Bioabsorbable Concepts Ltd | Monifunktionaalinen implanttilaite |
| US7163920B2 (en) | 2003-09-30 | 2007-01-16 | Ethicon, Inc. | Peptide with osteogenic activity |
| CU23352A1 (es) | 2003-10-16 | 2009-03-16 | Centro Nacional De Investigaciones Cientificas | Biomateriales compuestos para implantes óseos |
| WO2005042048A2 (en) | 2003-10-22 | 2005-05-12 | Encelle, Inc. | Bioactive hydrogel compositions for regenerating connective tissue |
| US20050098915A1 (en) | 2003-11-07 | 2005-05-12 | Smith & Nephew Inc. | Manufacture of bone graft substitutes |
| AU2004291111A1 (en) | 2003-11-14 | 2005-06-02 | The Trustees Of The University Of Pennsylvania | Method and device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip |
| DE10355559A1 (de) | 2003-11-21 | 2005-06-23 | Orthogen Ag | Transskin |
| EP1537839A1 (en) | 2003-12-02 | 2005-06-08 | Dr. h. c. Robert Mathys Foundation | Prosthetic device for cartilage repair |
| GB2426706A (en) | 2004-01-16 | 2006-12-06 | Inst Of Nutraceutical Res Pty | Glycosaminoglycan peptides derived from connective tissues and use thereof in the prevention of arthritis and other degenerative medical conditions |
| EP1708651A4 (en) | 2004-01-27 | 2011-11-02 | Osteotech Inc | STABILIZED BONE PROOF |
| US7189263B2 (en) | 2004-02-03 | 2007-03-13 | Vita Special Purpose Corporation | Biocompatible bone graft material |
| US11395865B2 (en) | 2004-02-09 | 2022-07-26 | DePuy Synthes Products, Inc. | Scaffolds with viable tissue |
| US7671012B2 (en) | 2004-02-10 | 2010-03-02 | Biosurface Engineering Technologies, Inc. | Formulations and methods for delivery of growth factor analogs |
| US7928059B2 (en) | 2004-02-24 | 2011-04-19 | Wisconsin Alumni Research Foundation | Use of neuropeptides for traumatic cartilage injury |
| KR101013999B1 (ko) | 2004-03-19 | 2011-02-14 | 재단법인서울대학교산학협력재단 | 표면에 골조직 형성 증진 펩타이드가 고정된 차폐막 및임플란트 |
| US20070190101A1 (en) | 2004-03-31 | 2007-08-16 | Chunlin Yang | Flowable bone grafts |
| WO2006031388A2 (en) | 2004-08-20 | 2006-03-23 | Hyperbranch Medical Technology, Inc. | Dentritic polymers, crosslinked gels, and their uses in orthopedic applications |
| GB2432845A (en) | 2004-09-21 | 2007-06-06 | Massachusetts Inst Technology | Gradient scaffolding and methods of producing the same |
| US7390489B2 (en) * | 2004-10-08 | 2008-06-24 | Komed Co., Ltd. | Monoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody |
| US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
| US7250550B2 (en) | 2004-10-22 | 2007-07-31 | Wright Medical Technology, Inc. | Synthetic bone substitute material |
| WO2006050493A2 (en) | 2004-11-03 | 2006-05-11 | The Regents Of The University Of Michigan | Biodegradable implant for intertransverse process fusion |
| US20060149392A1 (en) | 2004-12-07 | 2006-07-06 | Kuo-Huang Hsieh | Biomaterials for guided tissue regeneration and drug delivery |
| US20060151383A1 (en) | 2005-01-12 | 2006-07-13 | Aaf-Mcquay Inc. | Pleated corrugated media and method of making |
| US7621963B2 (en) | 2005-04-13 | 2009-11-24 | Ebi, Llc | Composite bone graft material |
| ES2516690T5 (es) | 2005-06-07 | 2017-11-21 | The Regents Of The University Of Colorado, A Body Corporate | Inhibidores de la actividad de serina proteasa y su uso en métodos y composiciones para el tratamiento de rechazo de injertos y promoción de supervivencia de injertos |
| KR20080084808A (ko) | 2005-11-17 | 2008-09-19 | 바이오미메틱 세라퓨틱스, 인크. | ｒｈＰＤＧＦ-ＢＢ 및 생체적합성 매트릭스를 사용하는상악안면골 보강 |
| US7749555B2 (en) | 2006-01-25 | 2010-07-06 | Medtronic, Inc | Modification of chemical forces of bone constructs |
| WO2007090102A2 (en) | 2006-01-27 | 2007-08-09 | The Regents Of The University Of California | Biomimetic scaffolds |
| US20070178159A1 (en) | 2006-01-30 | 2007-08-02 | Alza Corporation | In-Situ Forming Porous Scaffold |
| EP2311505B1 (en) | 2006-02-09 | 2013-11-06 | BioMimetic Therapeutics, LLC | Compositions and methods for treating bone |
| US7833270B2 (en) | 2006-05-05 | 2010-11-16 | Warsaw Orthopedic, Inc | Implant depots to deliver growth factors to treat osteoporotic bone |
| US8460860B2 (en) | 2006-05-08 | 2013-06-11 | Nuvasive, Inc. | Cancellous bone treated with collagenase and essentially free of blood cells |
| EP3381463A1 (en) | 2006-06-30 | 2018-10-03 | BioMimetic Therapeutics, LLC | Pdgf-biomatrix compositions and methods for treating rotator cuff injuries |
| US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
| CA2668189C (en) | 2006-11-03 | 2016-01-26 | Biomimetic Therapeutics, Inc. | Compositions and methods for arthrodetic procedures comprising a solution of platelet derived growth factor (pdgf) incorporated in a biocompatible matrix |
| WO2008100442A1 (en) | 2007-02-09 | 2008-08-21 | Biomet Biologics, Inc. | Treatment of tissue defects with a therapeutic composition |
| US20100151025A1 (en) | 2007-02-20 | 2010-06-17 | Biomimetic Therapeutics, Inc. | Prevention and treatment for osteonecrosis and osteoradionecrosis of the jaw |
| CA2689986C (en) | 2007-06-04 | 2020-04-07 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating the vertebral column |
| AU2008265850B2 (en) | 2007-06-15 | 2014-06-26 | Warsaw Orthopedic, Inc. | Bone matrix compositions and methods |
| DK2185197T3 (en) | 2007-08-22 | 2018-12-10 | Noveome Biotherapeutics Inc | New cell factor-containing solution compositions and their use for wound treatment |
| US7993679B2 (en) | 2007-09-25 | 2011-08-09 | Integra Lifesciences Corporation | Flowable wound matrix and its preparation and use |
| CN102014977B (zh) | 2008-02-07 | 2015-09-02 | 生物模拟治疗有限责任公司 | 用于牵引成骨术的组合物和方法 |
| CN102231992B (zh) | 2008-09-09 | 2015-05-20 | 生物模拟治疗公司 | 用于治疗肌腱和韧带损伤的血小板衍生生长因子的组合物和方法 |
| EP2376106A4 (en) | 2008-12-19 | 2013-01-09 | Biomimetic Therapeutics Inc | BONE TRANSPLANTS WITH REDUCED PROTEASE EFFECT AND SELECTION AND APPLICATION PROCEDURES |
| US20100247651A1 (en) | 2009-03-05 | 2010-09-30 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods for the treatment of osteochondral defects |
-
2006
- 2006-11-17 KR KR1020087014535A patent/KR20080084808A/ko not_active Ceased
- 2006-11-17 US US11/601,376 patent/US8114841B2/en active Active
- 2006-11-17 NZ NZ571113A patent/NZ571113A/en not_active IP Right Cessation
- 2006-11-17 EP EP06837973A patent/EP1951327A2/en not_active Withdrawn
- 2006-11-17 JP JP2008541379A patent/JP5368102B2/ja not_active Expired - Fee Related
- 2006-11-17 CA CA2630077A patent/CA2630077C/en active Active
- 2006-11-17 EP EP11165354.9A patent/EP2431060B1/en active Active
- 2006-11-17 WO PCT/US2006/044766 patent/WO2007061889A2/en not_active Ceased
- 2006-11-17 CN CNA2006800511547A patent/CN101370531A/zh active Pending
- 2006-11-17 BR BRPI0618794-3A patent/BRPI0618794A2/pt not_active IP Right Cessation
-
2008
- 2008-05-26 ZA ZA2008/04548A patent/ZA200804548B/en unknown
- 2008-05-27 NO NO20082393A patent/NO20082393L/no not_active Application Discontinuation
-
2012
- 2012-01-05 US US13/344,506 patent/US20120128774A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8114841B2 (en) | 2012-02-14 |
| NO20082393L (no) | 2008-08-15 |
| US20120128774A1 (en) | 2012-05-24 |
| EP2431060A2 (en) | 2012-03-21 |
| BRPI0618794A2 (pt) | 2011-09-13 |
| CA2630077C (en) | 2014-07-15 |
| CN101370531A (zh) | 2009-02-18 |
| EP2431060B1 (en) | 2020-04-08 |
| AU2006318689A1 (en) | 2007-05-31 |
| WO2007061889A3 (en) | 2008-02-21 |
| US20070129807A1 (en) | 2007-06-07 |
| ZA200804548B (en) | 2012-02-29 |
| CA2630077A1 (en) | 2007-05-31 |
| EP2431060A3 (en) | 2012-07-25 |
| WO2007061889A2 (en) | 2007-05-31 |
| EP1951327A2 (en) | 2008-08-06 |
| JP2009515668A (ja) | 2009-04-16 |
| NZ571113A (en) | 2012-02-24 |
| JP5368102B2 (ja) | 2013-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8114841B2 (en) | Maxillofacial bone augmentation using rhPDGF-BB and a biocompatible matrix | |
| JP6116484B2 (ja) | 脊椎固定術用の組成物および方法 | |
| van Oirschot et al. | Fast degradable calcium phosphate cement for maxillofacial bone regeneration | |
| Wen et al. | Bone tissue engineering around dental implants | |
| Sheikh et al. | Bone grafting | |
| Casap et al. | Recombinant human bone morphogenetic protein-2 confined by an imperforate titanium shell over high-profile dental implants in rabbit tibiae: a pilot bone augmentation study. | |
| Park et al. | Vertical and horizontal ridge augmentation using customized three-dimensionally printed polycaprolactone mesh in atrophic posterior maxillae: a case report | |
| AU2006318689B2 (en) | Maxillofacial bone augmentation using rhPDGF-BB and a biocompatible matrix | |
| MX2008006373A (en) | Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix | |
| Liu et al. | Pilot study of a calcium phosphate cement based composite as implant coating and socket grafting material | |
| Kader et al. | Recombinant human bone morphogenetic protein-2 versus autogenous bone graft in the reconstruction of maxillary anterior alveolar ridge defects | |
| 周天任 | Injectable porous bioresorbable composite containing fluvastatin for bone augmentation | |
| Lacerda Schickert et al. | Stabilizing dental implants with a fiber-reinforced calcium phosphate cement: An in vitro and in vivo study | |
| MEKCHA | CUSTOM 3D PRINTED HYDROXYAPATITE BONE BLOCK GRAFT FOR ALVEOLAR RIDGE RECONSTRUCTION: A PILOT CLINICAL STUDY | |
| Glogauer | Bone Grafting | |
| Zeng | Application of poly (trimethylene carbonate) and calcium phosphate composite biomaterials in oral and maxillofacial surgery | |
| Zhou et al. | Evaluation of Osteogenic Efficiency of an Inorganic Ceramic Material for Repair of Canine Alveolar Clefts | |
| AU2017213462A1 (en) | Compositions and methods for spine fusion procedures | |
| Leventis et al. | Research Article Minimally Invasive Alveolar Ridge Preservation Utilizing an In Situ Hardening 𝛽-Tricalcium Phosphate Bone Substitute: A Multicenter Case Series | |
| Kumarswamy | In vivo assessment of osseous wound healing using bone putty in the surgical management of tooth extractions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20080616 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20111117 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20130314 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20131127 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20140513 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20131127 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20130314 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |